EU/3/04/245

Table of contents

About

On 16 November 2004, orphan designation (EU/3/04/245) was granted by the European Commission to PharmaMar SA Sociedad Unipersonal, Spain, for aplidine for the treatment of multiple myeloma.

Key facts

Active substance
Aplidine
Disease / condition
Treatment of multiple myeloma
Date of first decision
16/11/2004
Outcome
Positive
EU designation number
EU/3/04/245

Sponsor's contact details

Phama Mar S.A. Sociedad Unipersonal
Polígono Industrial La Mina
Avda de los Reyes 1
E-28770 Colmenar Viejo
Madrid
Spain
Telephone: +34 91 84 66 000
Telefax: +34 91 84 66 001
E-mail: pharmamar@pharmamar.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

How useful was this page?

Add your rating